Business Context and Reporting Period
This Form 6-K filing by SciSparc Ltd. covers the month of May 2026, with the report dated May 29, 2026. The filing primarily discloses a material corporate development involving the Company's subsidiary, NeuroThera Labs Inc. ("NeuroThera").
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a transactional update regarding an acquisition.
Material Changes and Transaction Details
- Regulatory Approval: On May 28, 2026, NeuroThera received conditional regulatory approval to acquire CliniQuantum Ltd. ("CliniQuantum").
- Transaction Amendment: On April 30, 2026, an amendment was executed to the Share Purchase Agreement (originally dated March 9, 2026) regarding the acquisition.
- Completion Date Extension: The closing date for the transaction was extended from April 30, 2026, to June 1, 2026.
- Earn-out Pricing: The amendment stipulates that any NeuroThera common shares issued for earn-out payments will be valued at a deemed price of not less than $0.05 per share, adhering to the minimum permitted price under TSX Venture Exchange policies.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance, management commentary on future performance, or a discussion of general risk factors. The primary contingency noted is the conditional nature of the regulatory approval for the CliniQuantum acquisition.
Investor Verification Checklist
- Verify the specific conditions attached to the regulatory approval for the CliniQuantum acquisition.
- Confirm the final closing date of the transaction, currently targeted for June 1, 2026.
- Review the full text of the April 30, 2026 Amendment (Exhibit 10.1) for additional terms regarding the earn-out structure.
- Assess the impact of the $0.05 minimum share price on potential dilution for existing shareholders.